The 52-week, randomized, double-blind, placebo-controlled study investigated the LDL-C lowering efficacy and the safety and tolerability of bempedoic acid 180mg in comparison to placebo. It was carried out
The post Esperion’s cholesterol drug bempedoic acid succeeds in phase 3 trial appeared first on Pharma Business review.
Original Article: Esperion’s cholesterol drug bempedoic acid succeeds in phase 3 trial